← 返回

基于大分割放疗诱导的 MDSC 时空变化与趋化机制的优化 CAR-T 治疗

英文原题:Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy.

查看英文原题

Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy.

PubMed 2023/04/17(内容时间) Mol Ther Q1 · IF 11.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

实体瘤CAR-T 治疗最大障碍是肿瘤内浸润不足。低分割放疗(HFRT)据报可诱导免疫细胞浸润并重塑肿瘤免疫微环境。本研究发现,在免疫健全的三阴性乳腺癌或结肠癌小鼠中,HFRT(5×5 Gy)早期会导致肿瘤内髓源抑制细胞(MDSC)积聚并减少T细胞浸润;患者肿瘤中也观察到类似变化。RNA测序和细胞因子分析显示,HFRT通过多种趋化因子及受体相互作用,激活并促进肿瘤浸润MDSC增殖。进一步研究发现,HFRT联合阻断CXCR2可显著抑制MDSC向肿瘤迁移,有效提高CAR-T 肿瘤内浸润及治疗效果。研究提示MDSC阻断联合HFRT有望优化实体瘤CAR-T 治疗。

展开英文摘要原文

Poor intratumoral infiltration is the major challenge for chimeric antigen receptor (CAR)-T cell therapy in solid tumors. Hypofractionated radiotherapy (HFRT) has been reported to induce immune cell infiltration and reshape the tumor immune microenvironment.

Here, we showed that HFRT (5 5 Gy) mediated an early accumulation of intratumoral myeloid-derived suppressor cells (MDSCs) and decreased infiltration of T cells in the tumor microenvironment (TME) of immunocompetent mice bearing triple-negative breast cancer (TNBC) or colon cancer, which was further confirmed in tumors from patients.

RNA sequencing (RNA-seq) and cytokine profiling analysis revealed that HFRT induced the activation and proliferation of tumor-infiltrated MDSCs, which was mediated by the interactions of multiple chemokines and chemokine receptors.

Further investigation showed that when combined with HFRT, CXCR2 blockade significantly inhibited MDSCs trafficking to tumors and effectively enhanced the intratumoral infiltration and treatment efficacy of CAR-T cells.

Our study demonstrates that MDSCs blockade combined with HFRT is promising for CAR-T cell therapy optimization in solid tumors.

论文信息

作者
Zhang B、Hu M、Ma Q、Li K、Li X、He X、Shu P、Chen Y
第一作者单位
Division of Thoracic Tumor Multimodality Treatment, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.China
通讯作者单位
Division of Thoracic Tumor Multimodality Treatment, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: wangys@scu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Molecular therapy : the journal of the American Society of Gene Therapy2023 Jul 5
原文标识
PubMed 37073129 · DOI 10.1016/j.ymthe.2023.04.008